Printer Friendly

The Trend for Steadily Increasing U.S. Drug Prices is No Longer Certain.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c61028) has announced the addition of Decision Resources Inc.'s new report: 2007 Chartbook of International Pharmaceutical Prices to their offering.

Pharmaceutical companies are increasingly subjected to the dynamics of a globalized pharmaceutical market, and drug pricing and reimbursement continue to vary widely country to country. In a price-sensitive environment such as this, pharmaceutical companies increasingly need to be aware of international price differentials. Through 20 tables and 10 figures of ex-manufacturer prices of 160 of the world's best-selling prescription drugs sold in seven of the world's largest pharmaceutical markets, this report examines overall price differentials, reviews the pricing hierarchy in individual markets, analyzes price variation by therapeutic areas, and examines the pricing of biologics.

Questions Answered in This Spectrum Report:

- Automatic price increases for drugs in the United States have been the norm for years, but now relatively high drug prices in the United States have provoked widespread criticism, and the trend for steadily increasing U.S. prices is no longer certain. What pricing reforms are members of the Democratic U.S. Congress considering? Which biologics companies have already taken action to moderate prices on specific agents in the United States?

- Germany and the United Kingdom have the highest overall prices within Europe for the 160 drugs examined in this report. Why aren't these high prices necessarily producing high sales? Which European country had the lowest overall prices in 2006?

- In 2006, the price of 23 drugs in the United States was more than four times the average price in other markets. Which drugs were these? Precisely how much more expensive were these drugs compared to their prices in the United States?

- Overall, the prices in Europe of the 160 drugs analyzed in this report were only 54% of U.S. prices in 2006. How much did prices vary from country to country across Europe in relation to the United States? How much did prices vary among therapeutic areas?

- European and Japanese reimbursement authorities generally restrict pharmaceutical prices. However, these authorities have approved prices for biologics that are high in absolute terms and relative to U.S. prices. What factors does European and Japanese tolerance for the high prices of biologics likely reflect?

Scope:

- Overall price differentials among seven major pharmaceutical markets: ex-manufacturer prices of 160 drugs in six major markets (France, Germany, Italy, Spain, United Kingdom, and Japan) relative to U.S. prices; U.S. prices as a percentage of average prices in the other six major markets.

- Pricing hierarchy in individual markets: U.S. prices of 160 drugs as a percentage of average prices the six other major markets; prices in each of the six other major markets for the same 160 drugs as a percentage of U.S. prices.

- Price variations by therapeutic area: prices in six major markets compared to U.S. prices, tabulated for 20 drugs in each of seven therapeutic areas (cardiovascular drugs, metabolic disease therapies, immune and inflammatory disease therapies, infectious disease therapies, neurology drugs, psychiatric drugs, and antineoplastic drugs) as well as for 10 gastrointestinal drugs and 10 treatments for the side effects of chemotherapy.

- Biologics: prices as a percentage of U.S. prices for 22 biologics in the six other major markets.

- Outlook and Implications: uncertainty for increasing prices in the United States; pricing pressures from European reference-pricing policies; the uncertain relationship between high price and high sales in Europe; relentless erosion of prices in Japan.

Executive Summary

Strategic Considerations

Stakeholder Implications

Overview

Overall Price Differentials Among Markets

Pricing Hierarchy in Individual Markets

Price Variations by Therapeutic Area

Cardiovascular Drugs

Metabolic Disease Therapies

Immune and Inflammatory Disease Therapies

Infectious Disease Therapies

Neurology Drugs

Psychiatric Drugs

Antineoplastic Drugs

Treatments for the Side Effects of Chemotherapy

Gastrointestinal Drugs

Prices of Biologics

Outlook and Implications for the Pharmaceutical Industry

Tables

1. Dosages Used for Pricing Calculations

2. Ex-Manufacturer Prices of Select Best-Selling Prescription Drugs Expressed as a Percentage of U.S. Prices

3. U.S. Prices as a Percentage of Average Prices in the Other Six Major Pharmaceutical Markets

4. French Prices as a Percentage of U.S. Prices

5. German Prices as a Percentage of U.S. Prices

6. Italian Prices as a Percentage of U.S. Prices

7. Spanish Prices as a Percentage of U.S. Prices

8. U.K. Prices as a Percentage of U.S. Prices

9. Average European Prices as a Percentage of U.S. Prices

10. Japanese Prices as a Percentage of U.S. Prices

11. Prices of Leading Cardiovascular Drugs in the Major Markets as a Percentage of U.S. Prices

12. Prices of Leading Metabolic Disease Therapies in the Major Markets as a Percentage of U.S. Prices

13. Prices of Leading Immune and Inflammatory Disease Therapies in the Major Markets as a Percentage of U.S. Prices

14. Prices of Leading Infectious Disease Therapies in the Major Markets as a Percentage of U.S. Prices

15. Prices of Leading Neurological Disease Therapies in the Major Markets as a Percentage of U.S. Prices

16. Prices of Leading Psychiatric Drugs in the Major Markets as a Percentage of U.S. Prices

17. Prices of Leading Antineoplastic Drugs in the Major Markets as a Percentage of U.S. Prices

18. Prices of Leading Treatments for the Side Effects of Chemotherapy in the Major Markets as a Percentage of U.S. Prices

19. Prices of Leading Gastrointestinal Drugs in the Major Markets as a Percentage of U.S. Prices

20. Prices of Leading Biologics in the Major Markets as a Percentage of U.S. Prices

Figures

1. Average Prices of Leading Cardiovascular Drugs in the Major Markets as a Percentage of U.S. Prices

2. Average Prices of Leading Metabolic Disease Therapies in the Major Markets as a Percentage of U.S. Prices

3. Average Prices of Leading Immune and Inflammatory Disease Therapies in the Major Markets as a Percentage of U.S. Prices

4. Average Prices of Leading Infectious Disease Therapies in the Major Markets as a Percentage of U.S. Prices

5. Average Prices of Leading Neurological Disease Therapies in the Major Markets as a Percentage of U.S. Prices

6. Average Prices of Leading Psychiatric Disease Therapies in the Major Markets as a Percentage of U.S. Prices

7. Average Prices of Leading Antineoplastic Drugs in the Major Markets as a Percentage of U.S. Prices

8. Average Prices of Leading Treatments for the Side Effects of Chemotherapy in the Major Markets as a Percentage of U.S. Prices

9. Average Prices of Leading Gastrointestinal Drugs in the Major Markets as a Percentage of U.S. Prices

10. Average Prices of Leading Biologics, Small-Molecule Drugs, and Pharmaceuticals

Overall in the Major Markets as a Percentage of U.S. Prices

For more information visit http://www.researchandmarkets.com/reports/c61028
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 29, 2007
Words:1135
Previous Article:Sen. Dodd Selects MyLifeBrand Platform to Be Campaign's 24/7 Virtual Town Hall.
Next Article:Cypress Communications to Present Conference Session at INTERNET TELEPHONY(R) Conference & EXPO West 2007.
Topics:


Related Articles
Hours cast in shadow.
For birders in pursuit, no winging it.
Merry-go-round returns OSU to finals.
Birth outcomes improve for HIV-exposed infants.
Women who are fecund but do not wish to have children outnumber the involuntarily childless.
Prevalence of STDs is high for black young adults regardless of risk behavior.
U.S. Pipe to build first new ductile plant in more than 55 years.
Intermet sells European group.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters